Find Reports

Select Report Type

Learn More about Reports

Reimbursement Review

Displaying 1401 - 1422 of 1422

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 600 of 600

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 1551 - 1575 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Bavencio for metastatic Merkel Cell Carcinoma – Details	AvelumabBavencio_metastaticMerkelcellcarcinoma10124_ProvFunding2019-11-19.pdf pcodr_avelumab_bavencio_mcc_fn_rec.pdf pcodr_avelumab_bavencio_mcc_fn_cgr.pdf pcodr_avelumab_bavencio_mcc_fn_egr.pdf pcodr_avelumab_bavencio_mmcc_in_rec.pdf pcodr_avelumab_bavencio_mcc_pagfdk.pdf pcodr_avelumab_bavencio_mcc_espa.pdf pcodr_avelumab_bavencio_mcc_clnfdk.pdf pcodr_avelumab_bavencio_mcc_coi_pt.pdf pcodr_avelumab_bavencio_mcc_coi_cln.pdf	Apr 6, 2018	Reimbursement Review		Complete	PC0124-000
sofosbuvir velpatasvir voxilaprevir	SR0529_Vosevi_complete_Jan-25-18.pdf SR0529_Vosevi_CL_Report.pdf SR0529_Vosevi_PE_Report.pdf SR0529 Vosevi_Patient_Input.pdf	Apr 5, 2018	Reimbursement Review		Complete	SR0529-000
guselkumab	TS0001-PsO-Updated-Streamlined-Rec.pdf SR0530_Tremfya_complete_Feb-23-18.pdf SR0530_Tremfya_CL_Report.pdf SR0530_Tremfya_PE_Report.pdf SR0530_Tremfya_PI_Submissions.pdf	Apr 5, 2018	Reimbursement Review		Complete	SR0530-000
Gene Therapy: International Regulatory and Health Technology Assessment (HTA) Activities and Reimbursement Status		Mar 28, 2018	Health Technology Review	Environmental Scan	Completed	ES0325-000
fluocinolone acetonide		Mar 26, 2018	Reimbursement Review		Withdrawn	SR0549-000
Venclexta for Chronic Lymphocytic Leukemia – Details	pcodr_profund_venetoclax_venclexta_cll.pdf pcodr_venetoclax_venclexta_cll_fn_rec.pdf pcodr_venetoclax_venclexta_cll_fn_cgr.pdf pcodr_venetoclax_venclexta_cll_fn_egr.pdf pcodr_venetoclax_venclexta_cll_in_rec.pdf pcodr_venetoclax_venclexta_cll_pagfdk.pdf pcodr_venetoclax_venclexta_cll_fdk_abbvie.pdf pcodr_venetoclax_venclexta_cll_ptfdk.pdf pcodr_venetoclax_venclexta_cll_clnfdk.pdf pcodr_venetoclax_venclexta_cll_coi_pt.pdf pcodr_venetoclax_venclexta_cll_coi_cln.pdf	Mar 19, 2018	Reimbursement Review		Complete	PC0105-000
Keytruda for Metastatic Urothelial Carcinoma – Details	pcodr_provfund_pembrolizumab_keytruda_MUC.pdf pcodr_pembrolizumab_keytruda_muc_fn_rec.pdf pcodr_pembrolizumab_keytruda_muc_fn_cgr.pdf pcodr_pembrolizumab_keytruda_muc_fn_egr.pdf pcodr_pembrolizumab_keytruda_muc_in_rec.pdf pcodr_pembrolizumab_keytruda_muc_pagfdk.pdf pcodr_pembrolizumab_keytruda_muc_fdk_merck.pdf pcodr_pembrolizumab_keytruda_muc_clnfdk.pdf pcodr_pembrolizumab_keytruda_muc_coi_pt.pdf pcodr_pembrolizumab_keytruda_muc_coi_cln.pdf	Mar 19, 2018	Reimbursement Review		Complete	PC0117-000
Adcetris for Hodgkin’s Lymphoma (post-ASCT) Resubmission – Details	pcodr_profund_brentuximab_adcetris_hl_post-asct_resub.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_rec.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_cgr.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fn_egr.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_in_rec.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_pagfdk.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_fdk_sgi.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_clnfdk.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_coi_pt.pdf pcodr_brentuximab_adcetris_hl_post-asct_resub_coi_cln.pdf	Mar 8, 2018	Reimbursement Review		Complete	PC0116-000
migalastat	SR0522_Galafold_complete_Jan-26-18.pdf SR0522_Galafold_CL_Report.pdf SR0522_Galafold_PE_Report.pdf SR0522_Galafold_Patient_Input.pdf	Mar 1, 2018	Reimbursement Review		Complete	SR0522-000
ocrelizumab	SR0519_Ocrevus_RMS_complete_Nov-23-17.pdf SR0519_Ocrevus_RMS _PE_Report.pdf SR0519_Ocrevus_RMS_CL_Report.pdf SR0519_Ocrevus_RMS_PI_Submissions.pdf	Mar 1, 2018	Reimbursement Review		Complete	SR0519-000
lixisenatide	SR0520_Adlyxine_complete_Nov-23-17.pdf SR0520_Adlyxine_CL_Report.pdf SR0520_Adlyxine_PE_Report.pdf SR0520_Adlyxine_PI_Submissions.pdf	Mar 1, 2018	Reimbursement Review		Complete	SR0520-000
Faslodex for Locally Advanced or Metastatic Breast Cancer – Details	pcodr_provfund_fulvestrant_faslodex_mbc.pdf pcodr_fulvestrant_faslodex_mbc_fn_rec.pdf pcodr_fulvestrant_faslodex_mbc_fn_cgr.pdf pcodr_fulvestrant_faslodex_mbc_fn_egr.pdf pcodr_fulvestrant_faslodex_mbc_in_rec.pdf pcodr_fulvestrant_faslodex_mbc_pagfdk.pdf pcodr_fulvestrant_faslodex_mbc_fdk_asz.pdf pcodr_fulvestrant_faslodex_mbc_ptfdk.pdf pcodr_fulvestrant_faslodex_mbc_clnfdk.pdf pcodr_fulvestrant_faslodex_mbc_coi_pt.pdf pcodr_fulvestrant_faslodex_mbc_coi_cln.pdf	Feb 16, 2018	Reimbursement Review		Complete	PC0110-000
Drugs for Type 2 Diabetes: Second-Line Therapy Review Update		Feb 7, 2018	Health Technology Review	Therapeutic Review	Completed	TR0012-000
Cabozantinib for Advanced Renal Cell Carcinoma – Details		Jan 25, 2018	Reimbursement Review		Withdrawn	PC0123-000
insulin degludec	SR0521_Tresiba_complete_Nov-22-17_e.pdf SR0521_Tresiba_CL_Report.pdf SR0521_Tresiba_PE_Report.pdf SR0521_Tresiba_PI_Submissions.pdf	Jan 24, 2018	Reimbursement Review		Complete	SR0521-000
Pembrolizumab (Keytruda) classical Hodgkin Lymphoma – Details	pcodr_profund_pembrolizumab_keytruda_chl.pdf pcodr_pembrolizumab_keytruda_chl_fn_rec.pdf pcodr_pembrolizumab_keytruda_chl_fn_cgr.pdf pcodr_pembrolizumab_keytruda_chl_fn_egr.pdf pcodr_pembrolizumab_keytruda_chl_in_rec.pdf pcodr_pembrolizumab_keytruda_chl_pagfdk.pdf pcodr_pembrolizumab_keytruda_chl_fdk_merck.pdf pcodr_pembrolizumab_keytruda_chl_ptfdk.pdf pcodr_pembrolizumab_keytruda_chl_clnfdk.pdf pcodr_pembrolizumab_keytruda_chl_coi_pt.pdf pcodr_pembrolizumab_keytruda_chl_coi_cln.pdf	Jan 22, 2018	Reimbursement Review		Complete	PC0109-000
Onivyde for Metastatic Pancreatic Cancer – Details	pcodr_provfund_irinotecan_liposome_onivyde_mpc.pdf pcodr_irinotecan_liposome_onivyde_mpc_fn_rec.pdf pcodr_irinotecan_liposome_onivyde_mpc_fn_cgr.pdf pcodr_irinotecan_liposome_onivyde_mpc_fn_egr.pdf pcodr_irinotecan_liposome_onivyde_mpc_in_rec.pdf pcodr_irinotecan_liposome_onivyde_mpc_pagfdk.pdf pcodr_irinotecan_liposome_onivyde_mpc_clnfdk.pdf pcodr_irinotecan_liposome_onivyde_mpc_coi_pt.pdf pcodr_irinotecan_liposome_onivyde_mpc_coi_cln.pdf	Jan 22, 2018	Reimbursement Review		Complete	PC0107-000
Alternating Electric Fields ("Tumour- Treating Fields") for the Treatment of Glioblastoma		Jan 16, 2018	Horizon Scan	Emerging Health Technologies	Completed	EH0060-000
Fluticasone Furoate and Vilanterol (as trifenatate)	cdr_SR0442_Breo-Ellipta.pdf SR0442_complete_Breo Ellipta-Feb-22-16_e.pdf SR0442_BreoEllipta_CL_Report.pdf SR0442_BreoEllipta_PE_Report.pdf SR0442_BreoEllipta_PI_Submissions.pdf	Jan 15, 2018	Reimbursement Review		Complete	SR0442-000
Rydapt for Acute Myeloid Leukemia – Details	pcodr_profund_midostaurin_rydapt_aml.pdf pcodr_midostaurin_rydapt_all_fn_rec.pdf pcodr_midostaurin_rydapt_all_fn_cgr.pdf pcodr_midostaurin_rydapt_all_fn_egr.pdf pcodr_midostaurin_rydapt_all_in_rec.pdf pcodr_midostaurin_rydapt_all_pagfdk.pdf pcodr_midostaurin_rydapt_all_fdk_novartis.pdf pcodr_midostaurin_rydapt_all_clnfdk.pdf pcodr_midostaurin_rydapt_all_coi_pt.pdf pcodr_midostaurin_rydapt_all_coi_cln.pdf	Jan 11, 2018	Reimbursement Review		Complete	PC0108-000
Opdivo in combo with Yervoy for Metastatic Melanoma – Details	pcodr_profund_opdivo_yervoy_metmela.pdf pcodr_opdivo_yervoy_metmela_fn_rec.pdf pcodr_opdivo_yervoy_metmela_fn_cgr.pdf pcodr_opdivo_yervoy_metmela_fn_egr.pdf pcodr_opdivo_yervoy_metmela_in_rec.pdf pcodr_opdivo_yervoy_metmela_pagfdk.pdf pcodr_opdivo_yervoy_metmela_fdk_bms.pdf pcodr_opdivo_yervoy_metmela_ptfdk_mnc.pdf pcodr_opdivo_yervoy_metmela_ptfdk_sys.pdf pcodr_opdivo_yervoy_metmela_clfdk.pdf pcodr_opdivo_yervoy_metmela_coi_pt.pdf pcodr_opdivo_yervoy_metmela_coi_cl.pdf	Dec 18, 2017	Reimbursement Review		Complete	PC0098-000
abobotulinumtoxinA	dysport-therapeutic-product-monograph.pdf SR0517_complete_Dysport_Therapeutic_ULS_Oct_26-17_e.pdf SR0517_Dysport_Therapeutic_CL_Report.pdf SR0517_Dysport_Therapeutic_PE_Report.pdf SR0517_Dysport_ULS_PI_Submissions_Consolidated.pdf	Nov 23, 2017	Reimbursement Review		Complete	SR0517-000
Tafinlar & Mekinist in combo for Non-Small Cell Lung Cancer – Details	pcodr_provfund_tafinlar_mekinist_nsclc.pdf pcodr_tafinlar_mekinist_nsclc_fn_rec.pdf pcodr_tafinlar_mekinist_nsclc_fn_cgr.pdf pcodr_tafinlar_mekinist_nsclc_fn_egr.pdf pcodr_tafinlar_mekinist_nsclc_in_rec.pdf pcodr_tafinlar_mekinist_nsclc_pagfdk.pdf pcodr_tafinlar_mekinist_nsclc_fdk_novartis.pdf pcodr_tafinlar_mekinist_nsclc_ptfdk.pdf pcodr_tafinlar_mekinist_nsclc_clfdk.pdf pcodr_tafinlar_mekinist_nsclc_coi-cl.pdf pcodr_tafinlar_mekinist_nsclc_coi-pt.pdf	Nov 17, 2017	Reimbursement Review		Complete	PC0106-000
Darzalex for Multiple Myeloma (second-line or beyond) – Details	pcodr_profund_10104_daratumumab_darzalex_mm_2ln_beyond.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_rec.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_cgr.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_egr.pdf pcodr_daratumumab_darzalex_mm_2ndln_in_rec.pdf pcodr_daratumumab_darzalex_mm_2ndln_pagfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_fdk_janssen.pdf pcodr_daratumumab_darzalex_mm_2ndln_ptfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_clfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_coi_pt.pdf pcodr_daratumumab_darzalex_mm_2ndln_coi_cl.pdf	Oct 24, 2017	Reimbursement Review		Complete	PC0104-000
Lynparza for Ovarian Cancer (Resubmission) – Details	pcodr_profund_olaparib_lynparza_resub.pdf pcodr_olaparib_lynparza_resub_fn_rec.pdf pcodr_olaparib_lynparza_resub_fn_cgr.pdf pcodr_olaparib_lynparza_resub_fn_egr.pdf pcodr_olaparib_lynparza_resub_in_rec.pdf pcodr_olaparib_lynparza_resub_pagfdk.pdf pcodr_olaparib_lynparza_resub_fdk_astrazeneca.pdf pcodr_olaparib_lynparza_resub_ptfdk.pdf pcodr_olaparib_lynparza_resub_clinfdk.pdf pcodr_olaparib_lynparza_resub_coi_pt.pdf pcodr_olaparib_lynparza_resub_coi_clin.pdf	Oct 5, 2017	Reimbursement Review		Complete	PC0103-000